Eton Pharmaceuticals, Inc. (ETON): M&A transaction — Eton files historical financials for Increlex acquisition; product net sales $18.7M in 2023

Eton Pharmaceuticals, Inc.

Acquired Increlex for $22.5M upfront plus $7.5M inventory; $2.5M payments on 1st & 2nd anniversaries.
Expanded credit facility to $30M, maturity 3 years, SOFR+6.75%; issued warrant for 289,736 shares at $5.32.
Increlex net sales: $18.7M (2023), $15.1M (2022); nine months Sep 2024 $13.0M vs $13.9M prior.
Pro forma combined net loss for nine months Sep 2024: $5.5M vs Eton historical $3.2M.
Increlex net sales exceeded direct expenses: $3.9M in 2023, $4.1M in nine months Sep 2024.

item 2.01 item 9.01 item 8.01 item 9.0

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Eton Pharmaceuticals, Inc. completed an acquisition involving Ipsen S.A. (closed 2024-12-19).

Action: acquisition
Counterparty: Ipsen S.A.
Closing: 2024-12-19

Exact text from the filing

on December 1 9, 2024, the Company completed its purchase (the “Acquisition”) of Increlex® (“Increlex”) from Ipsen S.A. (“Ipsen”).

View on SEC.gov

Browse all m&a transactions →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-035597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.